Vesalius

Seven dimensions of
a category-defining peptide platform.

There are a lot of peptide vendors. There is one path to publicly traded peptide therapeutics distributed exclusively through licensed physicians. Here is how we got here — and why due diligence keeps ending in our favor.

Seven reasons to look closer at the peptide longevity category.

A B2Doctor model built for the compliance era — and the first company aiming to bring it to public markets.

01

First-mover in public peptide therapeutics

Building the path to become the first publicly traded company dedicated exclusively to peptide and longevity therapeutics.

02

B2Doctor distribution

Products move through independent licensed providers — not consumers. That gives us a compliance-forward channel and a defensible position in a fast-evolving regulatory landscape.

03

Multi-format delivery platform

Subcutaneous formulations, transdermal patches, intranasal sprays, oral capsules, and topical formulations — engineered for the right molecule to reach the right tissue.

04

Regulatory-forward sourcing

cGMP-aligned manufacturing, third-party verification, and chain-of-custody documentation. Built to clear the bar that grey-market peptide vendors cannot.

05

Global advisory depth

Board members, scientific advisors, and strategic operators from regenerative medicine, biotech, capital markets, and integrative health — spanning North America, Europe, the UAE, and Asia-Pacific.

06

Strategic telehealth channels

Partnerships with leading telehealth operators extend reach to underserved patient populations through licensed clinicians.

07

Science you can audit

Every claim sourced. Mechanism explained. References available. We invite due diligence — from investors, providers, and the press alike.

Three lanes. One compliance-forward platform.

Whether you are a solo licensed provider, a clinical network, or a telehealth operator — there is a path to work with us.

  • 01

    Independent Providers

    Regenerative, integrative, longevity, and functional medicine practitioners adding compliant peptide therapeutics to their practice.

    Become a partner
  • 02

    Clinical Networks

    Multi-site groups and concierge medicine networks looking for a credentialed, audit-ready supplier with consistent national fulfillment.

    Talk to enterprise
  • 03

    Telehealth & Strategic Partners

    Co-branded therapeutic launches with telehealth leaders — bringing peptides to underserved populations.

    Explore partnerships

Built for the audit.
Designed for the future of medicine.

0+Board members, scientific & strategic advisors
0Continents with active provider relationships
0Delivery formats across the platform
0%cGMP-aligned manufacturing partners